Danish pharmaceutical company Novo Nordisk is expanding its presence in Spain by establishing a technological and digital center in Madrid. This center will provide crucial support for the company’s global operations. Novo Nordisk has already hired 19 specialists in data management and biostatistics to work on clinical trials. The company, known for its commitment to sustainability, has also partnered with Forética in Spain.

In terms of financial performance, Novo Nordisk reported a 42.5% increase in profit in the first half of 2023, totaling 39,242 million Danish crowns (€5.26 million). They have revised their year-end forecasts, anticipating a growth in operating profit of between 31% and 37%. This growth has been attributed to the success of Wegovy, a product that has seen its sales quadruple, reaching 12,081 million Danish crowns (€1.62 million). Novo Nordisk’s net sales for the first half of the year amounted to 107,667 million Danish crowns (€14.45 million), a 29% increase compared to the same period the previous year.

Article written by Eva Wesley|Image by Unsplash